Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C32H37NO6 |
| Molecular Weight | 531.6393 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COCCOC1=CC(OCCOC)=CC(CN2C3=C(C=CC=C3)C(=C2C(O)=O)C4=CC=C(C=C4)C(C)(C)C)=C1
InChI
InChIKey=OIDYMQICWGYEDR-UHFFFAOYSA-N
InChI=1S/C32H37NO6/c1-32(2,3)24-12-10-23(11-13-24)29-27-8-6-7-9-28(27)33(30(29)31(34)35)21-22-18-25(38-16-14-36-4)20-26(19-22)39-17-15-37-5/h6-13,18-20H,14-17,21H2,1-5H3,(H,34,35)
GlaxoSmithKline was developing GSK-376501 as an oral peroxisome proliferator-activated receptor gamma partial agonist. This compound participated in phase I clinical trials for the treatment and diagnostic of patients with Type 2 Diabetes Mellitus, however, GSK discontinued the study of GSK-376501.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB12654
Created by
admin on Sat Dec 16 08:51:38 GMT 2023 , Edited by admin on Sat Dec 16 08:51:38 GMT 2023
|
PRIMARY | |||
|
24946920
Created by
admin on Sat Dec 16 08:51:38 GMT 2023 , Edited by admin on Sat Dec 16 08:51:38 GMT 2023
|
PRIMARY | |||
|
7511RY999U
Created by
admin on Sat Dec 16 08:51:38 GMT 2023 , Edited by admin on Sat Dec 16 08:51:38 GMT 2023
|
PRIMARY | |||
|
1010412-80-2
Created by
admin on Sat Dec 16 08:51:38 GMT 2023 , Edited by admin on Sat Dec 16 08:51:38 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
